Back to results
US 12,264,190 B2Granted
Compositions and methods of treating cancer with chimeric antigen receptors
AssigneeAstraZeneca AB
InventorsGordon Moody, Maria Letizia Giardino Torchia, Michael Glen Overstreet, Ryan Gilbreth
Life of this patent
Estimating the term…
Abstract
This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.
Claims24
An isolated nucleic acid sequence encoding
- a) a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cell surface antigen;
- and
- b) an armoring molecule, wherein the armoring molecule comprises a TGF-β receptor type 2 dominant-negative (TGFβRIIDN), wherein the TGFβRIIDN comprises a wild-type TGF-β receptor type 2 truncated at residue 194, and
- wherein the antigen-binding domain is a single chain variable fragment (scFv) comprising the nucleic acid sequence of SEQ ID NO:
- 33.
2 more elements
A vector, comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cell surface antigen and an armoring molecule, wherein the nucleic acid sequence comprises SEQ ID NO:
- 46.
A cell, comprising:
- a nucleic acid sequence encoding a chimeric antigen receptor (CAR), and
- a TGFβRIIDN armoring molecule expressed on a surface of the cell, wherein the TGFβRIIDN comprises a wild-type TGF-β receptor type 2 truncated at residue 194,
- wherein the CAR comprises an antigen-binding domain, a transmembrane domain, a costimulatory domain, and a signal domain, and
- wherein the antigen-binding domain is a single chain variable fragment (scFv) comprising the nucleic acid sequence of SEQ ID NO:
- 33.
2 more elements
A cell, comprising:
- an anti-GPC3 chimeric antigen receptor (CAR) comprising an antigen binding domain, wherein the antigen binding domain comprises an antibody, Fab, or an scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL),
- wherein the VH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 37, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 38, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 39, and
- wherein the VL comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 40 or SEQ ID NO:
- 43, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 41 or SEQ ID NO:
- 44, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 42 or SEQ ID NO:
- 45;
- and
- a TGFβRIIDN armoring molecule comprising amino acids 478 to 671 of SEQ ID NO:
- 47.
12 more elements
A cell, comprising:
- an anti-GPC3 chimeric antigen receptor (CAR) comprising an antigen binding domain, wherein the antigen binding domain comprises a scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL),
- wherein the VH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 37, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 38, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 39, and
- wherein the VL comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 40, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 41, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 42;
- and
- a TGFβRIIDN armoring molecule expressed on the surface of the cell comprising amino acids 478 to 671 of SEQ ID NO:
- 47.
9 more elements
Dependencies are inferred from the claim text.